Talphera, a specialty pharmaceutical company, announced a conference call and webcast on November 12, 2026, to review its financial results for the third quarter ended September 30, 2026, and recent business developments. The company focuses on innovative therapies for medically supervised settings, with its lead product Niyad® under FDA Breakthrough Device Designation. Investors can access the event via phone or webcast, with a replay available for 90 days on Talphera's website.
Talphera's upcoming Q3 2026 financial results announcement provides context for readers following healthcare developments. For readers following the health sector, here is Pluang's market snapshot as of Nov 04, 2026 19:41 WIB: out of 150 priced health-sector US stocks, 121 rose and 23 fell today. Notable movers include Novo Nordisk A/S (NVO) with a price of USD 42.57 and a 1-day change of +5.92%, HCA Health Inc (HCA) at USD 490.00 with +5.86%, and Heron Therapeutics Inc (HRTX) at USD 0.30 with +5.37%.
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...
Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...
